Eric Swayze - 16 Oct 2023 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP Research
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze
Issuer symbol
IONS
Transactions as of
16 Oct 2023
Net transactions value
-$2,493
Form type
4
Filing time
18 Oct 2023, 18:40:51 UTC
Previous filing
02 Mar 2023
Next filing
02 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +125 $0.000000 125 16 Oct 2023 by Son F1
transaction IONS Common Stock Sale $2,493 -52 -42% $47.95 73 17 Oct 2023 by Son F2
holding IONS Common Stock 32,516 16 Oct 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Restricted Stock Unit Options Exercise $0 -125 -22% $0.000000 456 16 Oct 2023 Common Stock 125 $0.000000 by Son F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2 The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4 Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.